> Schering has cut its projected peak sales figure for the hormone replacement therapy Angeliq from €250 million per year to €150 million annually. Report
> Insmed has announced an offering of 20 million shares. Release
> Merck and Paratek have signed a deal to collaborate on the development of an antibiotic. Merck paid an undisclosed up front fee and agreed to pay up to $127 more in milestone payments for Paratek's PTK 0796, an antibiotic currently in Phase I testing. Release
> Chutes & Ladders: Allos Therapeutics has named Paul Berns as its new CEO. Report
> Massachusetts, New York, Rhode Island and North Carolina will compete for a $660 million biologics plant that has been blueprinted by Bristol-Myers Squibb. Report
> ChemDiv, a clinical research organization, has struck a deal to develop new therapies with Berlex, the U.S. affiliate of Schering. Release
> Avian flu: About one percent of the chickens sold in southern China's markets are infected with bird flu. Microbiologists gathered fecal samples from apparently healthy chickens to complete the study, which indicates a significantly higher risk of human exposure than health authorities had expected. Report
> Shares of Dyax slid after the company reported plans to sell 5.5 million shares. Report
> Evotec has achieved a second milestone in its research collaboration with Boehringer Ingelheim. Report
> Targeted Genetics has announced a $5 million offering of common stock. Release
And Finally… A new study on aging says that America's baby boomers will reach retirement age better educated and in better physical condition than earlier generations of America. That trend may have a profound impact on the healthcare industry. Article